Clinical data | |
---|---|
Trade names | Decaris, Ergamisol |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a697011 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Liver |
Elimination half-life | 3–4 hours |
Excretion | Kidney (70%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.035.290 |
Chemical and physical data | |
Formula | C11H12N2S |
Molar mass | 204.29 g·mol−1 |
3D model (JSmol) | |
Density | 1.31 g/cm3 |
Melting point | 60 °C (140 °F) |
Solubility in water | hydrochloride: 210 mg/mL (20 °C) |
| |
| |
(what is this?) (verify) |
Levamisole, sold under the brand name Ergamisol among others, is a medication used to treat parasitic worm infections, specifically ascariasis and hookworm infections.[1] It is taken by mouth.[2]
Side effects may include abdominal pain, vomiting, headache, and dizziness.[2] Use is not recommended during breastfeeding or the third trimester of pregnancy.[2] Serious side effects may include an increased risk of infection.[3] It belongs to the anthelmintic class of medications.[3]
Levamisole was invented in 1966 in Belgium by Janssen Pharmaceuticals.[4] It is on the World Health Organization's List of Essential Medicines.[5] Levamisole is also used as a dewormer for cattle.[6][7]
Valcor FDA label
was invoked but never defined (see the help page).